BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

Negotiated additions to China’s National Reimbursement Drug List continue to drive down drug prices and expand access to checkpoint inhibitors, a category increasingly covered by domestic companies. Of the 162 drugs that underwent price negotiations,...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

...Leqvio through its $9.7 billion acquisition of The Medicines Co....
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer. ImmunoGen Inc. (NASDAQ:IMGN) expects data next year from the...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

ImmunoGen has been signaling for months that it would soon strike a licensing deal in China for its lead antibody-drug conjugate. On Monday, the biotech said Huadong will gain the program’s rights for $40 million...
BioCentury | Oct 6, 2020
Deals

Data Bytes: BMS’s takeout of MyoKardia marks most expensive CV acquisition to date

...the next highest-valued cardiovascular acquisition. In 2019, Novartis AG (NYSE:NVS; SIX:NOVN) spent $9.7 billion on The Medicines Co....
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...submitted for review by U.S. and EU regulators. The pharma acquired inclisiran via its takeout of The Medicines Co....
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

With drugs approved this year now eligible for reimbursement, China’s updated plan for the National Drug Reimbursement List plan could increase pricing pressure on eligible PD-1/PD-L1 inhibitors. The National...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

Monday marks the final day the public can comment on a draft plan for China’s next National Drug Reimbursement List, which could be updated to include countermeasures for COVID-19-associated respiratory disease as well as more...
Items per page:
1 - 10 of 910
BioCentury | Dec 31, 2020
Regulation

119 drugs added to China’s reimbursement list, which includes more domestic PD-1s

Negotiated additions to China’s National Reimbursement Drug List continue to drive down drug prices and expand access to checkpoint inhibitors, a category increasingly covered by domestic companies. Of the 162 drugs that underwent price negotiations,...
BioCentury | Dec 12, 2020
Regulation

RNA therapies get another 2020 win with inclisiran approval

...Leqvio through its $9.7 billion acquisition of The Medicines Co....
BioCentury | Nov 18, 2020
Product Development

Annual BayHelix awards highlight China’s growing life sciences sector; HKEX’s Li, Zai’s Du, Innovent among winners

In an award ceremony recognizing eight achievements in the life sciences in China this year, BayHelix highlighted the rapid growth of financing and deals by China’s biopharma companies. Innovent took home the Company of the Year...
BioCentury | Oct 30, 2020
Finance

Oct. 29 Quick Takes: Ultragenyx, Scholar Rock, Galecto, Citrine-Bioprojet, miRagen-Viridian, Elpis, CASI-BioInvent

Ultragenyx, Scholar Rock offerings Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and Scholar Rock Holding Corp. (NASDAQ:SRRK) raised follow-ons late Wednesday. Ultragenyx raised $400 million, while Scholar Rock raised $200 million via the shares and prefunded warrants after its stock more...
BioCentury | Oct 28, 2020
Product Development

Data Byte: FOLR1 pipeline for cancer

At least four antibody-drug conjugates, one antibody and two vaccines targeting FOLR1 are in development to treat cancer. The lead program is in Phase III testing for ovarian cancer. ImmunoGen Inc. (NASDAQ:IMGN) expects data next year from the...
BioCentury | Oct 19, 2020
Deals

ImmunoGen chooses Huadong’s $40M upfront offer for Greater China rights to ADC

ImmunoGen has been signaling for months that it would soon strike a licensing deal in China for its lead antibody-drug conjugate. On Monday, the biotech said Huadong will gain the program’s rights for $40 million...
BioCentury | Oct 6, 2020
Deals

Data Bytes: BMS’s takeout of MyoKardia marks most expensive CV acquisition to date

...the next highest-valued cardiovascular acquisition. In 2019, Novartis AG (NYSE:NVS; SIX:NOVN) spent $9.7 billion on The Medicines Co....
BioCentury | Aug 25, 2020
Finance

Seeing path for cholesterol-lowering program, Forbion launches start-up to house former Dezima molecule

...submitted for review by U.S. and EU regulators. The pharma acquired inclisiran via its takeout of The Medicines Co....
BioCentury | Aug 20, 2020
Politics, Policy & Law

Updated plan for China’s reimbursement increases pricing pressure on checkpoint inhibitors

With drugs approved this year now eligible for reimbursement, China’s updated plan for the National Drug Reimbursement List plan could increase pricing pressure on eligible PD-1/PD-L1 inhibitors. The National...
BioCentury | Aug 8, 2020
Regulation

China’s updated reimbursement list likely to see COVID-19 therapies, more anti-PD-1s

Monday marks the final day the public can comment on a draft plan for China’s next National Drug Reimbursement List, which could be updated to include countermeasures for COVID-19-associated respiratory disease as well as more...
Items per page:
1 - 10 of 910